e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Different aspects of COPD exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease
A. Bircan, M. Gokirmak, O. Kilic, O. Ozturk, A. Akkaya (Isparta, Turkey)
Source:
Annual Congress 2007 - Different aspects of COPD exacerbations
Session:
Different aspects of COPD exacerbations
Session type:
Electronic Poster Discussion
Number:
1383
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Bircan, M. Gokirmak, O. Kilic, O. Ozturk, A. Akkaya (Isparta, Turkey). Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30: Suppl. 51, 1383
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Genetically elevated C-reactive protein and chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD
Year: 2009
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Source: Eur Respir J 2006; 27: 902-907
Year: 2006
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 363s
Year: 2007
C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Serum leptin levels in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 259s
Year: 2002
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Coexisting chronic diseases in COPD – cause of elevated level of C-reactive protein?
Source: Annual Congress 2007 - COPD and comorbidity
Year: 2007
Serum magnesium levels of patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003
Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Body composition and plasma levels of inflammatory biomarkers in COPD
Source: Eur Respir J 2010; 36: 1027-1033
Year: 2010
Serum interferon-gamma levels in chronic obstructive pulmonary disease and asthma patients: correlation with respiratory parameters
Source: Eur Respir J 2001; 18: Suppl. 33, 75s
Year: 2001
Relationships between C-reactive protein and disability in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2005 - Systemic effects of COPD
Year: 2005
Serum amyloid A in patients with stable chronic obstructive pulmonary disease
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015
High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Plasma fibrinogen in patients with chronic obstructive pulmonary disease (COPD) with or without secondary erythrocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 586s
Year: 2005
Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease
Source: Annual Congress 2008 - COPD
Year: 2008
Prognostic value of C-reactive protein in patients with severe to very severe chronic obstructive pulmonary disease
Source: Annual Congress 2006 - COPD and inflammation
Year: 2006
Heart rate variability, nocturnal hypoxemia and C-reactive protein in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2007 - COPD and comorbidity
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept